Financial Performance - The company reported revenue of approximately RMB 432.52 million for the year ending December 31, 2025, a decrease of 28.8% compared to RMB 607.75 million in 2024[5] - Gross profit for 2025 was RMB 327.94 million, down from RMB 491.37 million in 2024, reflecting a decline of 33.2%[5] - Net profit attributable to shareholders was RMB 2.49 million in 2025, significantly lower than RMB 21.09 million in 2024, marking an 88.2% decrease[5] - Adjusted net profit (non-IFRS measure) was RMB 31.75 million in 2025, down from RMB 51.87 million in 2024, a decline of 38.8%[5] - Revenue decreased by 29.0% from RMB 607.8 million in 2024 to RMB 432.5 million in 2025, primarily due to reduced sales of inhalation products, especially CF017[19] - CF017 sales revenue dropped by 40.0% from RMB 574.5 million in 2024 to RMB 344.7 million in 2025, attributed to pricing pressure and decreased market demand[19] - CF018 sales revenue increased significantly from RMB 23.9 million in 2024 to RMB 79.0 million in 2025, driven by its inclusion in the national medical insurance catalog[20] - Gross profit fell by 33.3% from RMB 491.4 million in 2024 to RMB 327.9 million in 2025, with gross margin declining from 80.9% to 75.8%[22] - The company recorded a profit of RMB 2.5 million, a significant decrease from RMB 21.1 million in 2024[32] - The adjusted profit (non-IFRS measure) for 2025 was RMB 31.8 million, down from RMB 51.9 million in 2024, reflecting a decline of approximately 38.8%[36] Market and Product Development - The company faced multiple pressures in 2025, including a decrease in average selling prices due to VBP updates and a lower incidence of respiratory infections, impacting short-term market demand[7] - CF017, the company's core product, generated revenue of approximately RMB 344.7 million in 2025, down from RMB 574.5 million in 2024, primarily due to changes in VBP terms[9] - CF018, a new product, saw revenue growth from RMB 1.3 million in 2023 to RMB 79.0 million in 2025, indicating strong market acceptance and acceleration post-reimbursement inclusion[10] - The company aims to transition from a single product-driven model to a more diversified revenue structure, focusing on becoming a global inhalation system platform company[8] - The company signed a strategic cooperation agreement with Akang Health in February 2025 to enhance chronic disease management, focusing on respiratory diseases, which will improve prescription handling, drug delivery, patient education, and long-term repurchase[12] - In March 2026, the company entered a strategic partnership with JD Health for the online exclusive launch of multiple new respiratory and nasal products over the next three years, aiming to enhance product launch efficiency and patient accessibility[12] - The nasal spray product family is entering a clearer monetization phase, with new drug clinical trial applications submitted in 2025, including mometasone furoate and levofloxacin nebulizers, and the approval of budesonide nasal spray in January 2026[13] - The company is developing over 20 candidate products for major markets and plans to achieve at least five new product approvals and commercial launches between 2026 and 2030[14] - The inhaled powder candidate drug ICF001 received IND approval in March 2026, targeting pulmonary arterial hypertension and interstitial lung disease-related pulmonary hypertension, with a focus on improving drug delivery and patient experience[15] - The inhaled powder candidate drug ICF004, aimed at treating progressive fibrotic interstitial lung disease, received IND approval in February 2026, demonstrating a differentiated distribution profile in preclinical studies[16] - The company is leading a new inhaled nucleic acid drug development project, focusing on siRNA delivery for respiratory diseases, which has been recognized as a major technological project in Jiangsu Province[17] - The company has developed a comprehensive delivery system for inhaled siRNA candidates, with the goal of creating the world's first approved inhaled siRNA drug for chronic respiratory diseases[17] Financial Position and Assets - The company's property, plant, and equipment increased from RMB 531.1 million as of December 31, 2024, to RMB 547.4 million as of December 31, 2025, primarily due to investments in production infrastructure for respiratory drug development[38] - Inventory decreased by 22.2% from RMB 47.2 million as of December 31, 2024, to RMB 36.7 million as of December 31, 2025, mainly due to a reduction in customer orders for the CF017 product[39] - Trade receivables surged from RMB 27.1 million as of December 31, 2024, to RMB 159.4 million as of December 31, 2025, attributed to longer settlement cycles and higher sales concentration in Q4 2025[40] - The trade receivables turnover days increased significantly from 9 days in 2024 to 79 days in 2025, reflecting changes in credit terms offered to distributors[41] - Cash and cash equivalents rose dramatically from RMB 81.9 million as of December 31, 2024, to RMB 414.9 million as of December 31, 2025, primarily due to net proceeds from a global offering[45] - Restricted cash and time deposits increased by 49.0% from RMB 5.1 million as of December 31, 2024, to RMB 7.6 million as of December 31, 2025, due to additional collateral deposits for procurement and construction obligations[44] - The company's trade payables and notes payable remained stable at RMB 20.6 million as of December 31, 2024, and RMB 21.4 million as of December 31, 2025[46] - The trade payables turnover days decreased from 75 days in 2024 to 73 days in 2025, indicating improved efficiency in managing payables[46] - Other payables and accrued expenses decreased by 38.0% from RMB 204.1 million as of December 31, 2024, to RMB 126.5 million as of December 31, 2025, primarily due to optimization of sales and distribution networks[47] - Cash and cash equivalents reached RMB 414.9 million as of December 31, 2025, with total current assets net value approximately RMB 696.2 million[48] - Interest-bearing borrowings increased from RMB 73.8 million as of December 31, 2024, to RMB 142.3 million as of December 31, 2025, mainly to support operational funding[51] - Capital expenditures decreased by 59.8% from RMB 174.0 million in 2024 to RMB 70.0 million in 2025, due to the completion of major construction projects[52] - The current ratio improved significantly to 4.59 as of December 31, 2025, compared to 1.88 as of December 31, 2024[55] - The company had no significant asset pledges as of December 31, 2025[58] - The company held approximately RMB 325.4 million in cash and bank balances denominated in USD as of December 31, 2025, an increase from RMB 4.3 million as of December 31, 2024[63] Corporate Governance and Compliance - The company has complied with the corporate governance code and maintained high standards of corporate governance since its listing on October 8, 2025[115] - The audit committee, consisting of three independent non-executive directors, reviewed the consolidated financial statements for the year ending December 31, 2025, with no significant changes in accounting policies[119] - The board of directors includes the chairman, executive directors, and independent non-executive directors[126] - The group did not recommend any dividend for the year ended December 31, 2025, consistent with the previous year[92] - The company has not identified any significant changes in the planned use of the net proceeds from the global offering[125] Future Outlook - The board maintains cautious yet firm confidence in the group's prospects for 2026, anticipating it to be a key year for growth and structural upgrades[67] - The domestic business is expected to improve visibility with the completion of brand volume under the VBP update plan and strategic partnerships with companies like Jiuzhoutong and JD Health[68] - The company aims to reduce reliance on a single product cycle and achieve more balanced growth through stable overseas deliveries and clinical advancements in its innovation pipeline[69]
长风药业(02652) - 2025 - 年度业绩